Janssen Pharmaceuticals has signed a collaboration agreement with the National Taiwan University (NTU) and the university’s hospital (NTUH) to cooperate on developing new drugs for treating hepatitis B. Despite the high success rate of viral suppression achieved by existing medications, the virus is currently incurable.
Chen Ding-shinn (陳定信), chair professor at National Taiwan University Medical College, said that there are more than 350 million people in the world infected with the hepatitis B virus (HBV), 60 to 70 percent of which are in Asia.
Every year, more than 600 thousand people die as a result of complications such as liver cirrhosis and liver cancer caused by the virus.
“HBV can be transmitted prenatally [from mother to child] or by having contact with an infected person. While less than 3 percent of adults infected with the virus develop chronic hepatitis, more than 90 percent of infected newborns do,” Chen said. “Those who have chronic or persistent hepatitis B are at a high risk of developing liver cirrhosis or liver cancer later in life.”
There are about 2.4 million HBV carriers in Taiwan, Chen said, adding that statistics in 2011 showed that deaths attributable to liver cancer ranked No. 2 on the list of leading causes of death for men and women.
“Eighty percent to 90 percent of liver cancer patients had chronic hepatitis B,” he said.
“However, after Taiwan started vaccinating newborns against HBV in 1984, the number of yearly infections has decreased,” Chen said.
While the nation’s vaccination plan is an effective prevention measure, “having better control over the source of infection is still out of reach. Interferon, an approved medication for treating HBV infections is effective in only one-third of patients, while another treatment, nucleoside analogue therapy, inhibits viral replication without completely eliminating the virus.”
The collaboration is intended to develop a treatment to tackle the disease, Jansen, NTU and NTUH said in a joint statement.
Chen Pei-jer (陳培哲), a professor at the Graduate Institute of Clinical Medicine in NTUH’s Medical College and the principal investigator of the collaboration, said the aim is to “accelerate the development of a new hepatitis B drug by combining the resources uniquely held by the respective partners.”
“NTU has been working in this research field for more than 50 years. NTU’s specialization and experience makes it peerless in the fields of drug research and development,” Chen Pei-jer said.
“Janssen has a large collection of compounds as drug candidates. They need a platform to see whether the candidates are safe and effective,” Chen Pei-jer added.
From the mouse model first established by the NTU research team for assaying anti-viral and immune-modulatory activity — an important indication of HBV eradication — and the woodchuck model, which demonstrates HBV activity most similar to that of human HBV, to recent clinical research, Taiwan has always been a leader in the field of HBV treatment, Chen Pei-jer said, adding that NTU’s research was “a complete line from bench to bedside and back.”
“We are aiming to take the lead in developing a new drug to fully eradicate HBV,” the lead investigator said.
Taiwan has received more than US$70 million in royalties as of the end of last year from developing the F-16V jet as countries worldwide purchase or upgrade to this popular model, government and military officials said on Saturday. Taiwan funded the development of the F-16V jet and ended up the sole investor as other countries withdrew from the program. Now the F-16V is increasingly popular and countries must pay Taiwan a percentage in royalties when they purchase new F-16V aircraft or upgrade older F-16 models. The next five years are expected to be the peak for these royalties, with Taiwan potentially earning
STAY IN YOUR LANE: As the US and Israel attack Iran, the ministry has warned China not to overstep by including Taiwanese citizens in its evacuation orders The Ministry of Foreign Affairs (MOFA) yesterday rebuked a statement by China’s embassy in Israel that it would evacuate Taiwanese holders of Chinese travel documents from Israel amid the latter’s escalating conflict with Iran. Tensions have risen across the Middle East in the wake of US and Israeli airstrikes on Iran beginning Saturday. China subsequently issued an evacuation notice for its citizens. In a news release, the Chinese embassy in Israel said holders of “Taiwan compatriot permits (台胞證)” issued to Taiwanese nationals by Chinese authorities for travel to China — could register for evacuation to Egypt. In Taipei, the ministry yesterday said Taiwan
Taiwan is awaiting official notification from the US regarding the status of the Agreement on Reciprocal Trade (ART) after the US Supreme Court ruled US President Donald Trump's global tariffs unconstitutional. Speaking to reporters before a legislative hearing today, Premier Cho Jung-tai (卓榮泰) said that Taiwan's negotiation team remains focused on ensuring that the bilateral trade deal remains intact despite the legal challenge to Trump's tariff policy. "The US has pledged to notify its trade partners once the subsequent administrative and legal processes are finalized, and that certainly includes Taiwan," Cho said when asked about opposition parties’ doubts that the ART was
If China chose to invade Taiwan tomorrow, it would only have to sever three undersea fiber-optic cable clusters to cause a data blackout, Jason Hsu (許毓仁), a senior fellow at the Hudson Institute and former Chinese Nationalist Party (KMT) legislator, told a US security panel yesterday. In a Taiwan contingency, cable disruption would be one of the earliest preinvasion actions and the signal that escalation had begun, he said, adding that Taiwan’s current cable repair capabilities are insufficient. The US-China Economic and Security Review Commission (USCC) yesterday held a hearing on US-China Competition Under the Sea, with Hsu speaking on
RSS